Analysis of Ki-67 expression with neoadjuvant anastrozole or tamoxifen in patients receiving goserelin for premenopausal breast cancer

Cancer

Volumn 119, Issue 4, 2013, Pages 704-713

  Iwata, Hiroji ^a   Masuda, Norikazu ^b   Sagara, Yasuaki ^c   Kinoshita, Takayuki ^d   Nakamura, Seigo ^e,m   Yanagita, Yasuhiro ^f   Nishimura, Reiki ^g   Iwase, Hirotaka ^h   Kamigaki, Shunji ⁱ   Takei, Hiroyuki ^j   Tsuda, Hitoshi ^d   Hayashi, Nobuya ^k   Noguchi, Shinzaburo ^l  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b OSAKA NATIONAL HOSPITAL   (Japan)

^c SAGARA HOSPITAL   (Japan)

^d NATIONAL CANCER CENTER HOSPITAL   (Japan)

^e ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

^f Gunma Cancer Center   (Japan)

^g KUMAMOTO CITY HOSPITAL   (Japan)

^h KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

ⁱ SAKAI MUNICIPAL HOSPITAL   (Japan)

^j SAITAMA CANCER CENTER   (Japan)

^k ASTRAZENECA   (United Kingdom)

^l OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^m SHOWA UNIVERSITY HOSPITAL   (Japan)

more..

Author keywords

anastrozole; aromatase inhibitor; biomarker; Ki 67; neoadjuvant; premenopausal breast cancer

Indexed keywords

ANASTROZOLE; ESTROGEN RECEPTOR; GOSERELIN; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; ADULT; ANTIGEN EXPRESSION; ARTICLE; BREAST CANCER; CANCER STAGING; CANCER SURGERY; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LARGE CORE NEEDLE BIOPSY; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHASE 3 CLINICAL TRIAL; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOUBLE-BLIND METHOD; FEMALE; GOSERELIN; HUMANS; KI-67 ANTIGEN; MIDDLE AGED; NEOADJUVANT THERAPY; NITRILES; PREDICTIVE VALUE OF TESTS; PREMENOPAUSE; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES;

EID: 84873409339     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.27818     Document Type: Article

References (36)

1. Goldhirsch A, Ingle JN, Gelber RD, Coates AS, Thurlimann B, Senn H-J,. Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol. 2009; 20: 1319-1329.
2. Jonat W, Kaufmann M, Blamey RW, et al. A randomised study to compare the effect of the luteinising hormone releasing hormone (LHRH) analogue goserelin with or without tamoxifen in pre- and perimenopausal patients with advanced breast cancer. Eur J Cancer. 1995; 31A: 137-142.
3. Jakesz R, Hausmaninger H, Kubista E, et al. Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate, and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5. J Clin Oncol. 2002; 20: 4621-4627.
4. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001; 19: 2596-2606.
5. Nabholtz JM, Buzdar A, Pollak M, et al. Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol. 2000; 18: 3758-3767.
6. Bonneterre J, Thurlimann B, Robertson JF, et al. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol. 2000; 18: 3748-3757.
7. Paridaens RJ, Dirix LY, Beex LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26: 4883-4890.
8. Baum M, Budzar AU, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet. 2002; 359: 2131-2139.
9. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365: 60-62.
10. Dowsett M, Cuzick J, Ingle J, et al. Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol. 2010; 28: 509-518.
11. Cuzick J, Sestak I, Baum M, et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 2010; 11: 1135-1141.
12. van de Velde CJ, Rea D, Seynaeve C, et al. Adjuvant tamoxifen and exemestane in early breast cancer (TEAM): a randomised phase 3 trial. Lancet. 2011; 377: 321-331.
13. Forward DP, Cheung KL, Jackson L, Robertson JF,. Clinical and endocrine data for goserelin plus anastrozole as second-line endocrine therapy for premenopausal advanced breast cancer. Br J Cancer. 2004; 90: 590-594.
14. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009; 360: 679-691.
15. Tan MC, Al Mushawah F, Gao F, et al. Predictors of complete pathological response after neoadjuvant systemic therapy for breast cancer. Am J Surg. 2009; 198: 520-525.
16. Semiglazov VF, Semiglazov VV, Dashyan GA, et al. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer. Cancer. 2007; 110: 244-254.
17. Weigel MT, Dowsett M,. Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer. 2010; 17: R245-R262.
18. Dowsett M, Smith IE, Ebbs SR, et al. Short-term changes in Ki-67 during neoadjuvant treatment of primary breast cancer with anastrozole or tamoxifen alone or combined correlate with recurrence-free survival. Clin Cancer Res. 2005; 11: 951s-958s.
19. Dowsett M, Smith IE, Ebbs SR, et al. Prognostic value of Ki-67 expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst. 2007; 99: 167-170.
20. Masuda N, Sagara Y, Kinoshita T, et al. Neoadjuvant anastrozole versus tamoxifen in patients receiving goserelin for premenopausal breast cancer (STAGE): a double-blind, randomised phase 3 trial. Lancet Oncol. 2012; 13: 345-352.
21. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000; 92: 205-216.
22. Allred DC, Harvey JM, Berardo M, Clark GM,. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998; 11: 155-168.
23. Sakamoto G, Inaji H, Akiyama F, et al. General rules for clinical and pathological recording of breast cancer 2005. Breast Cancer. 2005; 12 (suppl): S1-S27.
24. Kurosumi M, Takatsuka Y, Watanabe T, et al. Histopathological assessment of anastrozole and tamoxifen as preoperative (neoadjuvant) treatment in postmenopausal Japanese women with hormone receptor-positive breast cancer in the PROACT trial. J Cancer Res Clin Oncol. 2008; 134: 715-722.
25. Ellis MJ, Tao Y, Luo J, et al. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst. 2008; 100: 1380-1388.
26. Gnant M, Mlineritsch B, Stoeger H, et al. Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial. Lancet Oncol. 2011; 12: 631-641.
27. Goncalves R, Ma C, Luo J, Suman V, Ellis MJ,. Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer. Nat Rev Clin Oncol. 2012; 9: 223-229.
28. Dowsett M, Smith IE, Ebbs SR, et al. Proliferation and apoptosis as markers of benefit in neoadjuvant endocrine therapy of breast cancer. Clin Cancer Res. 2006; 12: 1024s-1030s.
29. Endo Y, Toyama T, Takahashi S, et al. High estrogen receptor expression and low Ki-67 expression are associated with improved time to progression during first-line endocrine therapy with aromatase inhibitors in breast cancer. Int J Clin Oncol. 2011; 16: 512-518.
30. Toi M, Saji S, Masuda N, et al. Ki-67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition. Cancer Sci. 2011; 102: 858-865.
31. Urruticoechea A, Smith IE, Dowsett M,. Proliferation marker Ki-67 in early breast cancer. J Clin Oncol. 2005; 23: 7212-7220.
32. Mlineritsch B, Tausch C, Singer C, et al. Exemestane as primary systemic treatment for hormone receptor positive post-menopausal breast cancer patients: a phase II trial of the Austrian Breast and Colorectal Cancer Study Group (ABCSG-17). Breast Cancer Res Treat. 2008; 112: 203-213.
33. Decensi A, Guerrieri-Gonzaga A, Gandini S, et al. Prognostic significance of Ki-67 labeling index after short-term presurgical tamoxifen in women with ER-positive breast cancer. Ann Oncol. 2011; 22: 582-587.
34. Ellis MJ, Suman VJ, Hoog J, et al. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype-ACOSOG Z1031. J Clin Oncol. 2011; 29: 2342-2349.
35. Ellis MJ, Ma C,. Letrozole in the neoadjuvant setting: the P024 trial. Breast Cancer Res. Treat. 2007; 105 (suppl 1): 33-43.
36. Eiermann W, Paepke S, Appfelstaedt J, et al. Preoperative treatment of postmenopausal breast cancer patients with letrozole: a randomized double-blind multicenter study. Ann Oncol. 2001; 12: 1527-1532.